With the aim to overcome the deleterious effects of neutrophils in cancer, the IL-8 and CXCR1/CXCR2 inhibition could reduce neutrophils migration to the tumor, thus avoiding NETs formation and eventually preventing drug resistance. This evidence concerns the gene CXCL8 and cancer.